Aldeyra Therapeutics Presents Reproxalap Regulatory Update in Corporate Overview

• Aldeyra Therapeutics submitted a formal dispute resolution request for reproxalap in dry eye disease following three FDA complete response letters.
• The latest FDA letter found insufficient evidence of effectiveness but did not request further clinical trials.
• A meeting with the FDA's Office of New Drugs is expected in the fourth quarter of 2026.
• Cash and cash equivalents totaled $41 million as of September 30, 2026, sufficient to fund operations into 2029.
• AbbVie's licensing option includes a $100 million upfront payment less option fees, with a further $100 million contingent on FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.